1. Home
  2. PDS vs ABUS Comparison

PDS vs ABUS Comparison

Compare PDS & ABUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Precision Drilling Corporation

PDS

Precision Drilling Corporation

HOLD

Current Price

$96.30

Market Cap

918.1M

Sector

N/A

ML Signal

HOLD

Logo Arbutus Biopharma Corporation

ABUS

Arbutus Biopharma Corporation

HOLD

Current Price

$4.25

Market Cap

884.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PDS
ABUS
Founded
1951
2005
Country
Canada
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
918.1M
884.7M
IPO Year
1998
2008

Fundamental Metrics

Financial Performance
Metric
PDS
ABUS
Price
$96.30
$4.25
Analyst Decision
Buy
Strong Buy
Analyst Count
2
1
Target Price
$114.50
$5.00
AVG Volume (30 Days)
126.3K
2.2M
Earning Date
04-22-2026
03-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.64
EPS
N/A
N/A
Revenue
N/A
$6,171,000.00
Revenue This Year
$6.09
$125.30
Revenue Next Year
$2.10
N/A
P/E Ratio
$884.15
N/A
Revenue Growth
N/A
N/A
52 Week Low
$36.20
$2.71
52 Week High
$97.13
$5.10

Technical Indicators

Market Signals
Indicator
PDS
ABUS
Relative Strength Index (RSI) 72.77 43.73
Support Level $54.77 $4.23
Resistance Level N/A $4.76
Average True Range (ATR) 2.91 0.23
MACD 0.25 -0.05
Stochastic Oscillator 92.55 6.25

Price Performance

Historical Comparison
PDS
ABUS

About PDS Precision Drilling Corporation

Precision Drilling Corp is a provider of contract drilling and completion and production services to oil and natural gas exploration and production companies in Canada, the United States, and certain international locations. Contract Drilling Services include drilling rigs, procurement and distribution of oilfield supplies, and the manufacture, sale and repair of drilling equipment. Completion and Production Services include service rigs, oilfield equipment rental, and camp and catering services.

About ABUS Arbutus Biopharma Corporation

Arbutus Biopharma Corp is a clinical-stage biopharmaceutical company focused on infectious diseases. The company is leveraging its extensive virology expertise to identify and develop novel therapeutics with distinct mechanisms of action, which can be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). Its pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. In addition, the company is also focused on maximizing the opportunity for its in-house developed Lipid Nanoparticle (LNP) delivery technology.

Share on Social Networks: